Sponsor link to 3 opportunities Funding Opportunities- FY21 TSCRP, Congressionally Directed Medical Research Programs (CDMRP), US DoD (army.mil)

Applications submitted to the FY22 TSCRP Exploration – Hypothesis Development Award or Idea Development Award must address one or more of the following focus areas:

• Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions
• Strategies for eradicating tumors or other pathogenic lesions associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways and tumor microenvironment
• Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures

Applications submitted to the FY22 TSCRP Clinical Translational Research Award must address one or more of the following focus areas:

• Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
• Strategies for eradicating tumors or other pathogenic lesions associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM, including gaining a deeper mechanistic understanding of TSC signaling pathways and tumor microenvironment
• Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures

Exploration – Hypothesis Development Award – Letter of Intent due June 30, 2022

Investigators at all academic levels (or equivalent), including postdoctoral fellows

Supports the initial exploration of innovative, high-risk, high[1]gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field.

• • Projects involving human subjects or human biological substances must be exempt under Title 32 of the Code of Regulations, Part 219.104(d) (32 CFR 219.104(d)) or eligible for expedited review under 21 CFR 56.110.
• • Preliminary data not required.
• • Clinical trials not allowed.
• The maximum period of performance is 2 years.
• • The maximum allowable funding for the entire period of performance is $150,000 in direct costs.
• • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Idea Development Award – Letter of Intent June 30, 2022

Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) or New-to-the-Field Investigator: Independent investigators at or below the level of Assistant Professor (or equivalent) or Established Investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC

Promotes ideas that have the potential to yield high-impact findings and new avenues of investigation.

• • Preliminary data expected.
• • Clinical trials not allowed.
• • New-to-the-Field Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research.
• • Applications from New-to-the-Field Investigators and Established Investigators will compete separately.
• The maximum period of performance is 3 years.
• • The maximum allowable funding for the entire period of performance is $500,000 in direct costs.
• • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Translational Research Award – Letter of Intent due June 30, 2022

Independent Investigators at or above the level of Assistant Professor (or equivalent)

Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.

• • Applications may include correlative studies that are associated with a completed clinical trial.
• • Supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/ pharmacodynamics.
• • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• • Preclinical studies may be appropriate but must include a clinical component.
• • Projects that are exploratory and/or strictly animal research will not be considered for funding.
• • Collaborations between clinicians and research scientists are strongly encouraged.
• • Preliminary data required.
• • The maximum period of performance is 3 years.
• • The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs.
• • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.